Supernus Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDSupernus Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is weak (RS Rating: 37), showing significant lag compared to the market leaders. Earnings growth of 81% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $49.76 | +3.39% | ABOVE |
| 50 SMA | $50.98 | +0.93% | ABOVE |
| 100 SMA | $50.53 | +1.82% | ABOVE |
| 150 SMA | $49.79 | +3.33% | ABOVE |
| 200 SMA | $47.94 | +7.33% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SUPN in an uptrend right now?
SUPN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SUPN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SUPN overbought or oversold?
SUPN's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.
Is SUPN outperforming the market?
SUPN has a Relative Strength (RS) Rating of 37 out of 99. SUPN is currently lagging the broader market.
Where is SUPN in its 52-week range?
SUPN is trading at $51.45, which is 86% of its 52-week high ($59.68) and 73% above its 52-week low ($29.16).
How volatile is SUPN?
SUPN has a Beta of 0.78 and 52-week volatility of 35%. It's less volatile than the S&P 500 - generally more stable.